Results 11 to 20 of about 85,257 (242)
The Oncologist, 2010 AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F. +2 more
+8 more sources
American Journal of Neuroradiology, 2009 Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire +2 more sources
Bevacizumab for the Treatment of Glioblastoma
Clinical Medicine Insights: Oncology, 2013 Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months.
Gil Gil, Miguel +3 more
openaire +5 more sources
Hepatology, EarlyView., 2022 Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai +29 more
wiley +1 more source
Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor 15 upregulation [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Bevacizumab is a commonly used anticancer drug in clinical practice, but it often leads to adverse reactions such as vascular endothelial damage, hypertension, arterial and venous thrombosis, and bleeding.
Liqiang Chen +10 more
doaj +1 more source
MDM Policy & Practice, 2021 Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky +11 more
doaj +1 more source
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
Hepatology, EarlyView., 2022 In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie +17 more
wiley +1 more source
Cancer Medicine, 2020 Introduction Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs.
Jack Patrick Gleeson +13 more
doaj +1 more source
A five arm natural history study of nasal vestibulitis
Cancer Medicine, 2023 Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake +11 more
doaj +1 more source